Genetic epidemiology and public health: hope, hype, and future prospects

Genetic epidemiology is a rapidly expanding research field, but the implications of findings from such studies for individual or population health are unclear. The use of molecular genetic screening currently has some legitimacy in certain monogenic conditions, but no established value with respect to common complex diseases. Personalised medical care based on molecular genetic testing is also as yet undeveloped for common diseases. Genetic epidemiology can contribute to establishing the causal nature of environmentally modifiable risk factors, through the application of mendelian randomisation approaches and thus contribute to appropriate preventive strategies. Technological and other advances will allow the potential of genetic epidemiology to be revealed over the next few years, and the establishment of large population-based resources for such studies (biobanks) should contribute to this endeavour.

[1]  N. Risch.  Searching for genetic determinants in the new millennium , 2000, Nature.

[2]  M. Tobin,et al.  Commentary: development of Mendelian randomization: from hypothesis test to 'Mendelian deconfounding'. , 2004, International journal of epidemiology.

[3]  Muin J Khoury,et al.  The role of genetic polymorphisms in environmental health. , 2003, Environmental health perspectives.

[4]  G. Palomaki.  Prenatal screening for cystic fibrosis: An early report card , 2004, Genetics in Medicine.

[5]  Vitamin A and lung cancer. , 2009, Nutrition reviews.

[6]  R. Collins,et al.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[7]  Leroy Hood,et al.  The Code of Codes Scientific and Social Issues in the Human Genome Project , 1992 .

[8]  W. Evans,et al.  Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia , 2000, Leukemia.

[9]  R. Gray,et al.  How to avoid bias when comparing bone marrow transplantation with chemotherapy. , 1991, Bone marrow transplantation.

[10]  Lyle J Palmer,et al.  Genetic Epidemiology 4 Shaking the tree : mapping complex disease genes with linkage disequilibrium , 2022 .

[11]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[12]  Petra Verhoef,et al.  MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. , 2002, JAMA.

[13]  Shah Ebrahim,et al.  Association of C-Reactive Protein With Blood Pressure and Hypertension: Life Course Confounding and Mendelian Randomization Tests of Causality , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[14]  L. Cardon,et al.  The complex interplay among factors that influence allelic association , 2004, Nature Reviews Genetics.

[15]  S. Chanock,et al.  Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2 , 2004, Human Genetics.

[16]  S. Thibodeau,et al.  The APC E1317Q variant in adenomatous polyps and colorectal cancers. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  Steven J. Schrodi,et al.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. , 2004, American journal of human genetics.

[18]  K. Klinger,et al.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.

[19]  J Blangero,et al.  Large upward bias in estimation of locus-specific effects from genomewide scans. , 2001, American journal of human genetics.

[20]  E. Silverman,et al.  Case-control association studies for the genetics of complex respiratory diseases. , 2000, American journal of respiratory cell and molecular biology.

[21]  Muin J Khoury,et al.  Mendelian randomisation: a new spin or real progress? , 2003, The Lancet.

[22]  David V Conti,et al.  Commentary: the concept of 'Mendelian Randomization'. , 2004, International journal of epidemiology.

[23]  Chang-Gyu Hahn,et al.  Neurodevelopment, neuroplasticity, and new genes for schizophrenia. , 2005, Progress in brain research.

[24]  J. Bell.  Predicting disease using genomics , 2004, Nature.

[25]  J. Mcgrath.  Hypothesis: Is low prenatal vitamin D a risk-modifying factor for schizophrenia? , 1999, Schizophrenia Research.

[26]  N. Butler,et al.  National Child Development Study , 1974 .

[27]  Julie A. Johnson,et al.  Pharmacogenetics: potential for individualized drug therapy through genetics. , 2003, Trends in genetics : TIG.

[28]  C. Sabatti,et al.  Dissecting a population genome for targeted screening of disease mutations. , 2001, Human molecular genetics.

[29]  M. Khoury,et al.  Population screening in the age of genomic medicine. , 2003, The New England journal of medicine.

[30]  T. Marteau,et al.  Long-term cognitive and emotional impact of genetic testing for carriers of cystic fibrosis: the effects of test result and gender. , 1997, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[31]  P. McKeigue,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Problems of Reporting Genetic Associations with Complex Outcomes , 2022 .

[32]  B. Nordestgaard,et al.  Genetically Reduced Antioxidative Protection and Increased Ischemic Heart Disease Risk: The Copenhagen City Heart Study , 2003, Circulation.

[33]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[34]  N. Risch,et al.  Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. , 1995, JAMA.

[35]  S. Zubrick,et al.  Population screening for cystic fibrosis in Western Australia: community response. , 2000, American journal of medical genetics.

[36]  Wylie Burke,et al.  Genomics as a probe for disease biology. , 2003, The New England journal of medicine.

[37]  Barbara Burnaby.  A Personal View of ESL Materials Development in Canada with Reference to the Circle Project. , 1988 .

[38]  S. Ebrahim,et al.  Mendelian randomization: prospects, potentials, and limitations. , 2004, International journal of epidemiology.

[39]  J. Danesh,et al.  Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. , 2004, International journal of epidemiology.

[40]  Tw.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002, The Lancet.

[41]  T. McCarthy,et al.  Ryanodine receptor mutations in malignant hyperthermia and central core disease , 2000, Human mutation.

[42]  G. Smith,et al.  Reflections on the limitations to epidemiology. , 2001, Journal of clinical epidemiology.

[43]  R. Rosenberg.  Translating biomedical research to the bedside: a national crisis and a call to action. , 2003, JAMA.

[44]  John A. Todd,et al.  Parameters for reliable results in genetic association studies in common disease , 2002, Nature Genetics.

[45]  R. McManus,et al.  Pharmacogenetics of inflammatory bowel disease. , 2004, Novartis Foundation symposium.

[46]  Philippa J Talmud,et al.  Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[47]  F. Collins,et al.  Shattuck lecture--medical and societal consequences of the Human Genome Project. , 1999, The New England journal of medicine.

[48]  C. Rotimi,et al.  The new genetics in clinical practice , 1998, BMJ.

[49]  G. Davey Smith,et al.  Fibrinogen, C-reactive protein and coronary heart disease: does Mendelian randomization suggest the associations are non-causal? , 2004, QJM : monthly journal of the Association of Physicians.

[50]  S. Lewis,et al.  Meta-analysis of MTHFR 677C→ T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? , 2005, BMJ : British Medical Journal.

[51]  Richard Gray,et al.  Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. , 2004, International journal of epidemiology.

[52]  R. Myers,et al.  Candidate-gene approaches for studying complex genetic traits: practical considerations , 2002, Nature Reviews Genetics.

[53]  C. Waddington.  Canalization of Development and the Inheritance of Acquired Characters , 1942, Nature.

[54]  Muin J Khoury,et al.  The emergence of epidemiology in the genomics age. , 2004, International journal of epidemiology.

[55]  B. Winblad,et al.  Risk and protective effects of the APOE gene towards Alzheimer’s disease in the Kungsholmen project: variation by age and sex , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[56]  W F Bodmer,et al.  The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  P. Vineis,et al.  Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. , 1995, Journal of clinical epidemiology.

[58]  Paul R Burton,et al.  Key concepts in genetic epidemiology , 2005, The Lancet.

[59]  D. Christiani,et al.  Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[60]  B. Vastag.  Cystic Fibrosis Gene Testing a Challenge , 2003 .

[61]  L. Cardon,et al.  Association study designs for complex diseases , 2001, Nature Reviews Genetics.

[62]  Gudmundur A. Thorisson,et al.  The International HapMap Project Web site. , 2005, Genome research.

[63]  A. Coats.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[64]  Muin J Khoury,et al.  Can family history be used as a tool for public health and preventive medicine? , 2002, Genetics in Medicine.

[65]  B. Godard,et al.  Population genetic screening programmes: principles, techniques, practices, and policies , 2003, European Journal of Human Genetics.

[66]  Paul Brennan,et al.  Commentary: Mendelian randomization and gene-environment interaction. , 2004, International journal of epidemiology.

[67]  S. Shostak.  Locating gene-environment interaction: at the intersections of genetics and public health. , 2003, Social science & medicine.

[68]  P. Elwood,et al.  Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up , 2001, Heart.

[69]  M. Katan.  APOUPOPROTEIN E ISOFORMS, SERUM CHOLESTEROL, AND CANCER , 1986, The Lancet.

[70]  J. Chang-Claude,et al.  Familial risk and genetic susceptibility for breast cancer , 1994, Cancer Causes & Control.

[71]  R. Elswick,et al.  Screening for drinking problems by patient self-report. Even 'safe' levels may indicate a problem. , 1995, Archives of internal medicine.

[72]  M. Oscarson.  Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine , 2003, Clinical chemistry and laboratory medicine.

[73]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[74]  Nicholas W Wood,et al.  Genome scans and candidate gene approaches in the study of common diseases and variable drug responses. , 2003, Trends in genetics : TIG.

[75]  S. Michie,et al.  Incorrect recall of residual risk three years after carrier screening for cystic fibrosis: a comparison of two-step and couple screening. , 1999, American journal of obstetrics and gynecology.

[76]  P. Shekelle,et al.  Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease , 2004, Journal of General Internal Medicine.

[77]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[78]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[79]  E. Rimm,et al.  Vitamin E consumption and the risk of coronary heart disease in men. , 1993, The New England journal of medicine.

[80]  David Posada,et al.  Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction , 2004 .

[81]  Homocysteine and coronary heart disease amongst Indian Asians. , 2000, Indian heart journal.

[82]  D. Eccles.  Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  F. Clavel-Chapelon,et al.  Amount of DNA in plasma and cancer risk: A prospective study , 2004, International journal of cancer.

[84]  S. Lewis,et al.  Alcohol, ALDH2, and Esophageal Cancer: A Meta-analysis Which Illustrates the Potentials and Limitations of a Mendelian Randomization Approach , 2005, Cancer Epidemiology Biomarkers & Prevention.

[85]  D. English,et al.  ELAC 2 / HPC 2 Polymorphisms , Prostate-Specific Antigen Levels , and Prostate Cancer , 2003 .

[86]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[87]  E. Schaefer,et al.  Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. , 2004, Atherosclerosis.

[88]  M. Khoury,et al.  Genomic profiling to promote a healthy lifestyle: not ready for prime time , 2003, Nature Genetics.

[89]  S. Mascheretti.  Pharmacogenetics of inflammatory bowel disease$star;*1 , 2004 .

[90]  M. Schwartz,et al.  Psychological and social impact of carrier screening for cystic fibrosis among pregnant women — a pilot study , 1996, Clinical genetics.

[91]  E. Breeze,et al.  Design, objectives, and lessons from a pilot 25 year follow up re-survey of survivors in the Whitehall study of London Civil Servants. , 1998, Journal of epidemiology and community health.

[92]  Diana Petitti,et al.  Commentary: hormone replacement therapy and coronary heart disease: four lessons. , 2004, International journal of epidemiology.

[93]  J. Crowe,et al.  Genetic hemochromatosis, a Celtic disease: is it now time for population screening? , 2001, Genetic testing.

[94]  B. Keavney.  Commentary: Katan's remarkable foresight: genes and causality 18 years on. , 2004, International journal of epidemiology.

[95]  K. Weiss,et al.  How many diseases does it take to map a gene with SNPs? , 2000, Nature Genetics.

[96]  P. Workman.  The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones , 2003, Cancer Chemotherapy and Pharmacology.

[97]  C. Eng,et al.  Prenatal genetic carrier testing using triple disease screening. , 1997, JAMA.

[98]  W. Grody.  Molecular genetic risk screening. , 2003, Annual review of medicine.

[99]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[100]  M. Uusitupa,et al.  Does lactose intolerance predispose to low bone density? A population-based study of perimenopausal Finnish women. , 1996, Bone.

[101]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[102]  R. Norio.  Finnish Disease Heritage I: characteristics, causes, background. , 2003, Human genetics.

[103]  V. Gudnason,et al.  The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study. , 2001, Atherosclerosis.

[104]  W. Burke,et al.  Using pharmacogenetics to improve drug safety and efficacy. , 2004, JAMA.

[105]  G. Taubes.  Epidemiology faces its limits. , 1995, Science.

[106]  M. Khoury,et al.  An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions , 2004, Genetics in Medicine.

[107]  Peter P. Zandi,et al.  Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study , 2004 .

[108]  S. Ebrahim,et al.  What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? , 2005, BMJ : British Medical Journal.

[109]  W. Kalow,et al.  Pharmacogenetics and personalised medicine , 2002, Fundamental & clinical pharmacology.

[110]  David Clayton,et al.  Epidemiological methods for studying genes and environmental factors in complex diseases , 2001, The Lancet.

[111]  R. Edwards,et al.  Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer , 2004, British Journal of Cancer.

[112]  K. Buetow,et al.  The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. , 2001, Biochimica et biophysica acta.

[113]  A. Beaudet.  Making Genomic Medicine a Reality , 1999 .

[114]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[115]  W. Crosby,et al.  Hereditary hemochromatosis. , 1993, Journal of the American Medical Association (JAMA).

[116]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[117]  F. Collins,et al.  The family history--more important than ever. , 2004, The New England journal of medicine.

[118]  C. Niederau,et al.  Strategies for early diagnosis of haemochromatosis , 2002, European journal of gastroenterology & hepatology.

[119]  D. Lawlor,et al.  Clustering of risk factors and social class in childhood and adulthood in British women's heart and health study: cross sectional analysis , 2004, BMJ : British Medical Journal.

[120]  A. Hoes.  Case-control studies. , 1995, The Netherlands journal of medicine.

[121]  Robert Luben,et al.  Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study , 2001, The Lancet.

[122]  S. Zubrick,et al.  Population screening for cystic fibrosis: Knowledge and emotional consequences 18 months later , 2003, American journal of medical genetics. Part A.

[123]  P. Brennan,et al.  Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? , 2002, Carcinogenesis.

[124]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[125]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[126]  Sarah Parish,et al.  Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: Test of causality by "Mendelian randomisation" , 2000 .

[127]  C. Eng,et al.  Experiences in molecular-based prenatal screening for Ashkenazi Jewish genetic diseases. , 2001, Advances in genetics.

[128]  B. Ames.  Cancer prevention and diet: help from single nucleotide polymorphisms. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[129]  S. Thibodeau,et al.  The APC E 1317 Q Variant in Adenomatous Polyps and Colorectal Cancers 1 , 2003 .

[130]  David B. Goldstein,et al.  Pharmacogenetics goes genomic , 2003, Nature Reviews Genetics.

[131]  B. Garvik,et al.  Principles for the Buffering of Genetic Variation , 2001, Science.

[132]  Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis. , 1999, Archives of internal medicine.

[133]  M. Scheuner.  Genetic evaluation for coronary artery disease , 2003, Genetics in Medicine.

[134]  L. Bautista.  Association of C-reactive protein with blood pressure. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[135]  W. Grody,et al.  Prenatal screening for cystic fibrosis: past, present and future , 2004, Expert review of molecular diagnostics.

[136]  A. Wilkins,et al.  Canalization: a molecular genetic perspective. , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[137]  Francis S. Collins,et al.  The case for a US prospective cohort study of genes and environment , 2004, Nature.

[138]  Weimin Sun,et al.  Cystic fibrosis screening: Lessons learned from the first 320,000 patients , 2004, Genetics in Medicine.

[139]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[140]  G. D. Whedon,et al.  Osteoporosis, intestinal lactase deficiency and low dietary calcium intake. , 1967, The New England journal of medicine.

[141]  D. Lawlor,et al.  Commentary: the rough world of nutritional epidemiology: does dietary fibre prevent large bowel cancer? , 2003, International journal of epidemiology.

[142]  K. Lee,et al.  Validity of self-report in alcoholism research: results of a Veterans Administration Cooperative Study. , 1988, Alcoholism, clinical and experimental research.

[143]  N. Risch,et al.  Genomic Priorities and Public Health , 2003, Science.

[144]  D. McGill,et al.  Lactase deficiency: prevalence in osteoporosis. , 1978, Annals of internal medicine.

[145]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[146]  D. English,et al.  ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. , 2003, Journal of the National Cancer Institute.

[147]  H. Wolf,et al.  N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark , 1979, Environmental health perspectives.